News
Nurse scheduling often is a complex, high-level puzzle that needs to balance the demands of hospital operations and nurses' ...
Artificial intelligence (AI) models such as ChatGPT are designed to rapidly process data. Using the AI ChatGPT-4 platform to ...
11h
MedPage Today on MSNIdentifying High-Risk Multiple Myeloma"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...
It only takes four words to sum up the culture of a Connecticut health care system that is the only one in the nation that ...
16h
IFLScience on MSNStratus: What Are The Symptoms Of The Latest COVID-19 Subvariant To Spread Around The World?As Professor of Infectious Diseases and Microbiology Paul Griffin explains in a recent piece for The Conversation, Stratus is ...
The Trump administration’s cuts have pushed many lifetime civil servants out. They have also disrupted people at the other end of the career spectrum: interns.
2h
News-Medical.Net on MSNChatGPT matches radiologists in pancreatic cyst analysisArtificial intelligence (AI) models such as ChatGPT are designed to rapidly process data. Using the AI ChatGPT-4 platform to extract and analyze specific data points from the Magnetic Resonance ...
Ceramedix Completes New York University’s Highly Selective Endless Frontier Labs Accelerator Program
Company Seeks Capital to Further Validate Proof of Concept Results and Prepare for Eventual IND Submission Following Critical ...
Key TakeawaysMRI and CT scans of nearly 1,000 adults were evaluated by ChatGPT-4 and the traditional manual approach for pancreatic cysts. The ...
HealthDay News — For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), according to a ...
Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results